3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Suspended
1
Sponsor Class
OTHER_GOV
1
Study Type
Interventional
1
Sponsor
Conditions
Breast Neoplasms
17
Uterine Cervical Neoplasms
11
Stomach Neoplasms
11
Carcinoma, Non-Small-Cell Lung
11
Ovarian Neoplasms
8
Neoplasms
8
Esophageal Neoplasms
8
Carcinoma, Ovarian Epithelial
7
Fallopian Tube Neoplasms
6
Colorectal Neoplasms
5
Recurrence
4
Neoplasm Metastasis
4
Multiple Myeloma
4
Mouth Neoplasms
4
Head and Neck Neoplasms
4
Esophageal Squamous Cell Carcinoma
4
Colonic Neoplasms
4
Carcinoma, Hepatocellular
4
Rectal Neoplasms
3
Nasopharyngeal Carcinoma
3
Lymphoma, Non-Hodgkin
3
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
3
Glioblastoma
3
Urinary Bladder Neoplasms
2
Prostatic Neoplasms
2
Polycystic Ovary Syndrome
2
Peripheral Nervous System Diseases
2
Melanoma
2
Lymphoma, Mantle-Cell
2
Lymphoma, Large B-Cell, Diffuse
2
Interventions
Heparin
1
Enoxaparin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
OTHER_GOV
×
Malignant Female Reproductive System Neoplasm
×
Clear all
NCT01356329
2016-05-13
Lovenox
National Guard Health Affairs
Phase 3
Suspended
150 enrolled